VACCIBODY
(VACC)

VACCIBODY

13:00:17 · Euronext Growth Oslo

13:00:17 · Valuta i NOK

Euronext Growth Oslo

Senast

68,8

Idag %

−2,69%

Idag +/-

−1,9

Köp

68,6

Sälj

68,9

Högst

71,4

Lägst

67,9

Omsatt (Antal)

37 420

13:00:17 · Euronext Growth Oslo

13:00:17 · Valuta i NOK

Euronext Growth Oslo

VACCIBODY

13:00:17 · Euronext Growth Oslo · Valuta i NOK

13:00:17 · Valuta i NOK

Euronext Growth Oslo

Senast

68,8

Utveckling idag

−2,69%

−1,9

Köp

68,6

Sälj

68,9

Högst

71,4

Lägst

67,9

Omsatt (Antal)

37 420

Utveckling

Visa volym

Orderdjup

Öppen

Antal

Köp

1 714

Sälj

Antal

1 761

Senaste avslut

Tid	Antal	Köpare	Säljare
12:30:34	363	-	-
12:30:34	300	-	-
12:26:27	687	-	-
12:26:27	126	-	-
12:26:27	100	-	-

Omsättning (NOK)

2 578 097

Mäklarstatistik

Ingen data hittades

Företagshändelser

Det finns inga angivna utdelningar

Nyheter & Analyser

Utveckling

Visa volym

Shareville*

Besök Shareville

Relaterade värdepapper

Inga Nordnet Markets Certifikat finns med underliggande värdepapper. Se övriga Certifikat

Nyheter & Analyser

Företagshändelser

Det finns inga angivna utdelningar

Orderdjup

Öppen

Antal

Köp

1 714

Sälj

Antal

1 761

Senaste avslut

Tid	Antal	Köpare	Säljare
12:30:34	363	-	-
12:30:34	300	-	-
12:26:27	687	-	-
12:26:27	126	-	-
12:26:27	100	-	-

Omsättning (NOK)

2 578 097

Mäklarstatistik

Ingen data hittades

Företagshändelser

Det finns inga angivna utdelningar

*Kommentarerna ovan kommer från shareville.se och har varken redigerats eller granskats av Nordnet. De innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna.

Nyckeldata

P/E
-
P/E*
-
P/B
-
P/S
-
Utdelning/aktie
-
EPS
-
Direktavkastning
-
EPS tillväxt*
-
PEG
-

*Baserat på estimat

Finansiell översikt

Resultaträkning ()

category_local

Balansräkning ()

category_local

Kassaflöde ()

category_local

Bolagsöversikt

Ingen sammanfattning finns tillgänglig.

Företagsnamn
-
VD
-
E-post
-
Hemsida
-
Säte
-
Antal anställda
-
Antal aktier
-
Börsvärde
-

Om värdepapperet

Namn
VACCIBODY
ISIN
-
Sektor
-
Bransch
-
Kortnamn
VACC
Introduktionsdatum
-
Antal ägare hos Nordnet
-
Belåningsgrad
-
Säkerhetskrav
200%
Blankningsbar
Nej

NorwayVACCIBODY (VACC)

NorwayVACCIBODY

NorwayVACCIBODY

NorwayVACCIBODY

Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider's related party

Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider's related party

VACC: Share capital increase from exercise of warrants

Vaccibody AS - Quarterly report Q2 2021

VACC: Vaccibody Q2 and half-year report 2021 webcast

VACC: Vaccibody enters into worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in a second-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of co

VACC: Share capital increase from exercise of warrants

VACC: Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern

VACC: Grant of Share Options

VACC: Vaccibody to present at Goldman Sachs 42nd Annual Global Healthcare Conference

Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider's related party

Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider's related party

VACC: Share capital increase from exercise of warrants

Vaccibody AS - Quarterly report Q2 2021

VACC: Vaccibody Q2 and half-year report 2021 webcast

VACC: Vaccibody enters into worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in a second-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of co

VACC: Share capital increase from exercise of warrants

VACC: Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern

VACC: Grant of Share Options

VACC: Vaccibody to present at Goldman Sachs 42nd Annual Global Healthcare Conference

Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider's related party

Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider's related party

VACC: Share capital increase from exercise of warrants

Vaccibody AS - Quarterly report Q2 2021

VACC: Vaccibody Q2 and half-year report 2021 webcast

VACC: Vaccibody enters into worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in a second-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of co

VACC: Share capital increase from exercise of warrants

VACC: Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern

VACC: Grant of Share Options

VACC: Vaccibody to present at Goldman Sachs 42nd Annual Global Healthcare Conference

Resultaträkning ()

Balansräkning ()

Kassaflöde ()

Om värdepapperet

VACCIBODY
(VACC)

VACCIBODY

VACCIBODY

VACCIBODY